Cullinan Therapeutics outlines fourth quarter 2026 milestones in T cell engager pipeline

Cullinan Therapeutics outlines fourth quarter 2026 milestones in T cell engager pipeline
Cullinan 2026 pipeline milestones

Cullinan Therapeutics has announced its planned milestones for the fourth quarter of 2026 across its immunology and oncology T cell engager portfolio.

The update includes anticipated clinical data releases for CLN-978, velinotamig, and CLN-049, underscoring the company’s ongoing research focus. Further details on these developments are expected closer to the outlined timeline.

Cullinan Therapeutics recently released Phase 3 REZILIENT3 trial data at WCLC26, with further details promised in an upcoming investor webcast, according to a previous announcement. The company has also scheduled a webcast in September to present Phase 3 REZILIENT3 results on zipalertinib plus chemotherapy, as noted in earlier disclosures. These efforts reflect Cullinan’s ongoing focus on advancing its clinical pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.